GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avid Bioservices Inc (NAS:CDMO) » Definitions » Equity-to-Asset

Avid Bioservices (Avid Bioservices) Equity-to-Asset : 0.40 (As of Jan. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Avid Bioservices Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Avid Bioservices's Total Stockholders Equity for the quarter that ended in Jan. 2024 was $180.2 Mil. Avid Bioservices's Total Assets for the quarter that ended in Jan. 2024 was $455.2 Mil. Therefore, Avid Bioservices's Equity to Asset Ratio for the quarter that ended in Jan. 2024 was 0.40.

The historical rank and industry rank for Avid Bioservices's Equity-to-Asset or its related term are showing as below:

CDMO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.17   Med: 0.45   Max: 0.75
Current: 0.4

During the past 13 years, the highest Equity to Asset Ratio of Avid Bioservices was 0.75. The lowest was 0.17. And the median was 0.45.

CDMO's Equity-to-Asset is ranked worse than
70.67% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs CDMO: 0.40

Avid Bioservices Equity-to-Asset Historical Data

The historical data trend for Avid Bioservices's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avid Bioservices Equity-to-Asset Chart

Avid Bioservices Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.68 0.39 0.29 0.41 0.42

Avid Bioservices Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.42 0.43 0.40 0.40

Competitive Comparison of Avid Bioservices's Equity-to-Asset

For the Biotechnology subindustry, Avid Bioservices's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avid Bioservices's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avid Bioservices's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Avid Bioservices's Equity-to-Asset falls into.



Avid Bioservices Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Avid Bioservices's Equity to Asset Ratio for the fiscal year that ended in Apr. 2023 is calculated as

Equity to Asset (A: Apr. 2023 )=Total Stockholders Equity/Total Assets
=189.47/451.054
=0.42

Avid Bioservices's Equity to Asset Ratio for the quarter that ended in Jan. 2024 is calculated as

Equity to Asset (Q: Jan. 2024 )=Total Stockholders Equity/Total Assets
=180.17/455.227
=0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avid Bioservices  (NAS:CDMO) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Avid Bioservices Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Avid Bioservices's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Avid Bioservices (Avid Bioservices) Business Description

Traded in Other Exchanges
Address
14191 Myford Road, Tustin, CA, USA, 92780
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development and high-quality CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.
Executives
Matthew R. Kwietniak officer: Chief Commercial Officer 14191 MYFORD ROAD, TUSTIN CA 92780
Richard A. Richieri officer: Chief Operations Officer 14191 MYFORD ROAD, TUSTIN CA 92780
Daniel Ryan Hart officer: Chief Financial Officer 2642 MICHELLE DR., SUITE 200, TUSTIN CA 62780
Mark R Ziebell officer: V.P., General Counsel 14282 FRANKLIN AVENUE, TUSTIN CA 92780
Richard B Hancock director 14282 FRANKLIN AVE., TUSTIN CA 92780
Joseph Carleone director 3883 HOWARD HUGHES PKWY, SUITE 700, LAS VEGAS NV 89169
Nicholas Stewart Green director, officer: President & CEO 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Gregory Sargen director
Esther M. Alegria director 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Mark R Bamforth director 500 KENDALL ST., CAMBRIDGE MA 02142
Jeanne Thoma director C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Joel Mccomb director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Stephen Michael Hedberg officer: Principal Fin. & Acct. Officer 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780

Avid Bioservices (Avid Bioservices) Headlines